个人简介

教育及工作情况： 2011.03 至今，上海药物研究所安评中心，课题组长； 2008.04-2011.03，诺华制药，美国波士顿，药代和早期药物安全性评价部高级研究员，机制实验室主管 2007.10-2008.03 诺华制药，美国波士顿，药代和早期药物安全性评价部初级研究员 2004.01-2007.09： 明尼苏达大学，博士后，同时进修高级药代动力学，群体药代动力学等 2000.09-2003.06： 博士，中国药科大学， 方向：药代动力学 1997.09-2000.06： 硕士, 中国药科大学； 方向：神经药理学； 1992.09-1997.06： 学士，方向：药理学

研究领域

主要从事药物诱导性肝脏损伤早期筛选平台的建立以及早期新药肝肾药物相互作用，药代动力学和安全性评价，同时领导药物所-阿斯利康联盟（SIMM-AstraZeneca Alliance）中药物制剂和生物分析工作。经过两年的建设，潘国宇课题组已经在药物的肝胆分布、肝脏毒性等领域取得显著进展

1. 早期DILI评价预测模型的开发，和DILI相关的药物相互作用和毒代动力学机制研究2. 新型肝样细胞系的研发，评价和在ADMET中的应用3. 中草药的代谢、肝毒性机制和药物相互作用

近期论文

Huang P, Zhang L, Gao Y, He Z, Yao D, Wu Z, Cen J, Chen X, Liu C, Hu Y, Lai D, Hu Z, Chen L, Zhang Y, Cheng X, Ma X, Pan G, Wang X, Hui L. Direct reprogramming of human fibroblasts to functional and expandable hepatocytes.Cell Stem Cell. 2014 Mar 6;14(3):370-84. Fu M1, Xu W, Lu Q, Pan G, Varga C. Evaluation and optimization of high-performance liquid chromatography coupled with high-resolution mass spectrometry for phospholipid quantitation. Rapid Commun Mass Spectrom. 2014 Apr 15;28(7):811-21. He, L., Yang, Y., Guo, C., Dan, Y., Liu, H. H., Sheng, J. J., ... & Pan, G. Y. Opposite regulation of hepatic breast cancer resistance protein in type 1 and 2 diabetes mellitus. European journal of pharmacology. Eur J Pharmacol. 2014 Feb 5;724:185-92. Guo, C., He, L., Yao, D., Cao, B., Ren, J., Wang, G., & Pan, G. Alpha-naphthylisothiocyanate modulates hepatobiliary transporters in sandwich-cultured rat hepatocytes. Toxicology letters, 2014. 224(1), 93-100. Tian, X., Li, Z., Lin, Y., Chen, M., Pan, G., & Huang, C. Study on the PK profiles of magnoflorine and its potential interaction in Cortex phellodendri decoction by LC-MS/MS. Analytical and bioanalytical chemistry, 2014 406(3), 841-849. Zhu, J., Ning, M., Guo, C., Zhang, L., Pan, G., Leng, Y., & Shen, J. Design, synthesis and biological evaluation of a novel class of potent TGR5 agonists based on a 4-phenyl pyridine scaffold. European journal of medicinal chemistry, 2013.69, 55-68. Pan G*, Boiselle C, Wang J*. Assessment of biliary clearance in early drugdiscovery using sandwich-cultured hepatocyte model. J Pharm Sci, 2012 Volume 101, Issue 5, pp1898-1908.Chen M, Gong L, Qi X, Xing G, Luan Y, Wu Y, Xiao Y, Yao J, Li Y, Xue X, Pan G,Ren J*. Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction ofaristolochic acid I and attenuates its nephrotoxicity. Toxicol Sci. 2011 Volume 122, Issue 2,pp 288-296.Liu H, Wu B, Pan G, He L, Li Z, Fan M, Jian L, Chen M, Wang K, Huang C*. Metabolism and Pharmacokinetics of Mangiferin in Conventional rats,Pseudo-germ-free rats, and Streptozotocin-induced Diabetic Rats. Drug MetabDispos. 2012. Volume 40, Issue 11, pp 2109-2118.Rong Zhang, Jianguo Sun*, Liping Ma, Xiaolan Wu, Guoyu Pan, HaipingHao, Fang Zhou, Jiye A, Changhui Liu, Lili Shang, HaiyanGao, Ping Wan, Hui Wu, Guangji Wang*. Induction of cytochromes P450 1A1 and 1A2 by tanshinones in human HepG2 hepatoma cell line. Toxicology and Applied Pharmacology, 2011 Volume 252, Issue 1, pp 18-27.Pan G, Winter TN, Roberts JC, Fairbanks CA, Elmquist WF*. Organic Cation Uptake Is Enhanced in bcrp1-Transfected MDCKII Cells. Mol Pharm, 2010. Volume 7, Issue 1, pp138-145.Giri, N., Agarwal, S., Shaik, N., Pan, G., Chen, Y., & Elmquist, W. F. Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metabolism and Disposition, 2009. 37(3), 560-570.